PolyMedix company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

polymedix.com

Stage

Asset Sale | AssetsPurchased

About PolyMedix

PolyMedix is a clinical stage biotechnology company developing small-molecule drugs designed to mimic the activity of host defense proteins (HDPs) for the treatment of infectious diseases and innate immunity disorders. PolyMedix's compounds are designed to imitate the mechanism of action of HDPs, which contribute to natural human immunity. In contrast to existing antibiotics, PolyMedix's brilacidin, was designed to exploit a method of bacterial cell killing, via biophysical membrane attack, against which bacteria have not shown development of resistance in multiple preclinical studies. Brilacidin showed efficacy similar to an active control, and was safely administered in a Phase 2 clinical trial in patients with ABSSSI caused by Staphylococcus aureus bacteria (including methicillin-resistant Staphylococcus aureus (MRSA)). PolyMedix has plans to initiate a Phase 2B dose optimization study with brilacidin in ABSSSI patients and also to develop brilacidin as a topical treatment for radiation and chemotherapy-induced cancer oral mucositis, a common and often debilitating complication of cancer treatments.

PolyMedix Headquarter Location

170 N Radnor-Chester Road Suite 300

Wayne, Pennsylvania, 19087,

United States

484-598-2370

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PolyMedix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PolyMedix is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

PolyMedix Patents

PolyMedix has filed 7 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/21/2012

8/13/2013

G protein coupled receptors, Clusters of differentiation, Angiology, Transcription factors, Proteins

Grant

Application Date

6/21/2012

Grant Date

8/13/2013

Title

Related Topics

G protein coupled receptors, Clusters of differentiation, Angiology, Transcription factors, Proteins

Status

Grant

Latest PolyMedix News

Beverly biotech Cellceutix looks to capitalize on its recent acquisition of PolyMedix

Oct 21, 2013

Less than two months after Beverly, Mass.-based Cellceutix Inc. snapped up PolyMedix Inc., a bankrupt biotech for $2.1 million in cash and 1.4 million shares of its stock, the company is saying it is on track for additional growth. With the acquisition of the Radnor, Pa. bankrupt biotech, Cellceutix (OTC: CTIX) disclosed today that it has doubled its initial pipeline and has prepared the company for the initiation of five Phase 2 clinical trials in 2014 including the Phase 2/3 trial of Pruri

  • Where is PolyMedix's headquarters?

    PolyMedix's headquarters is located at 170 N Radnor-Chester Road, Wayne.

  • What is PolyMedix's latest funding round?

    PolyMedix's latest funding round is Asset Sale.

  • Who are the investors of PolyMedix?

    Investors of PolyMedix include Cellceutix.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.